These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 38876965)
1. Bullous pemphigoid successfully treated with dupilumab. Martinez DAES; Periquito AFS; Roa GG; Lupi JP; Treu CM; Lupi O An Bras Dermatol; 2024; 99(5):778-780. PubMed ID: 38876965 [No Abstract] [Full Text] [Related]
2. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature. Klepper EM; Robinson HN Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978 [TBL] [Abstract][Full Text] [Related]
3. Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter. Zhang Y; Zhang J; Chen J; Lin M; Gong T; Cheng B; Ji C Australas J Dermatol; 2021 Nov; 62(4):525-527. PubMed ID: 34448201 [No Abstract] [Full Text] [Related]
4. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature. Saleh M; Reedy M; Torok H; Weaver J Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579 [TBL] [Abstract][Full Text] [Related]
5. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L Front Immunol; 2020; 11():611549. PubMed ID: 33584689 [TBL] [Abstract][Full Text] [Related]
6. Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab. Rodríguez-Cuadrado FJ; Roustan-Gullón G; Suárez-Massa D; Hospital-Gil M An Bras Dermatol; 2024; 99(5):783-785. PubMed ID: 38876967 [No Abstract] [Full Text] [Related]
7. Successful treatment of bullous pemphigoid with omalizumab. London VA; Kim GH; Fairley JA; Woodley DT Arch Dermatol; 2012 Nov; 148(11):1241-3. PubMed ID: 23165827 [No Abstract] [Full Text] [Related]
8. A severe case of IgA bullous pemphigoid successfully treated with dupilumab. Valenti M; De Giacomo P; Lavecchia A; Valenti G Dermatol Ther; 2022 Nov; 35(11):e15890. PubMed ID: 36181411 [No Abstract] [Full Text] [Related]
9. Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab. Pascolini G; Mariotti F; Pira A; Didona B; Di Zenzo G Acta Derm Venereol; 2024 Oct; 104():adv41984. PubMed ID: 39387672 [No Abstract] [Full Text] [Related]
10. Successful dupilumab treatment in bullous pemphigoid complicated with subacute hematogenous disseminated tuberculosis: A case report. Dong Q; Zheng R; He Z; Xi Y Skin Res Technol; 2024 Jul; 30(7):e13847. PubMed ID: 38995310 [No Abstract] [Full Text] [Related]
11. Case report: Dupilumab for the treatment of bullous pemphigoid. Wang M; Wang J; Shi B Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478 [TBL] [Abstract][Full Text] [Related]
12. Severe pemphigoid nodularis successfully treated with dupilumab. Jendoubi F; Bost C; Tournier E; Paul C; Konstantinou MP Dermatol Ther; 2022 Sep; 35(9):e15727. PubMed ID: 35861645 [No Abstract] [Full Text] [Related]
13. Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients. Miller AC; Temiz LA; Adjei S; Duran MA; Sassmannshausen J; Dominguez A; Thomas C; Schmidt JD; Bernhardt M; Doolittle-Amieva CJ; Moshiri AS; Thompson AJ; Pyoung Kim-Lim P; Mattia AV; Tyring SK J Drugs Dermatol; 2024 Jun; 23(6):e144-e148. PubMed ID: 38834228 [TBL] [Abstract][Full Text] [Related]
14. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab. Halling AS; Zachariae C; Thyssen JP Contact Dermatitis; 2020 Jul; 83(1):37-38. PubMed ID: 32087035 [No Abstract] [Full Text] [Related]
15. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid. Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C Front Immunol; 2021; 12():738907. PubMed ID: 34721404 [TBL] [Abstract][Full Text] [Related]
16. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. Abdat R; Waldman RA; de Bedout V; Czernik A; Mcleod M; King B; Gordon S; Ahmed R; Nichols A; Rothe M; Rosmarin D J Am Acad Dermatol; 2020 Jul; 83(1):46-52. PubMed ID: 32179082 [TBL] [Abstract][Full Text] [Related]
17. Dupilumab for bullous pemphigoid with intractable pruritus. Seidman JS; Eichenfield DZ; Orme CM Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045153 [TBL] [Abstract][Full Text] [Related]
18. Dupilumab as a novel therapy for bullous pemphigoid. Zhang X; Man X; Tang Z; Dai R; Shen Y Int J Dermatol; 2023 Apr; 62(4):e263-e266. PubMed ID: 36440691 [No Abstract] [Full Text] [Related]
19. Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem. Mutton T; Bocchi C; Gaban A; Marzola E; Schettini N; Borghi A Ital J Dermatol Venerol; 2024 Jun; 159(3):361-363. PubMed ID: 38695597 [No Abstract] [Full Text] [Related]
20. A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis. Wang G; Hu X; Han S; Zhou M J Dermatolog Treat; 2024 Dec; 35(1):2366535. PubMed ID: 38945532 [No Abstract] [Full Text] [Related] [Next] [New Search]